Unveiling Our New Look

You may notice a few changes with this issue. First, we have changed our name from CMIO to Clinical Innovation + Technology. This reflects the ever-growing responsibilities facing hospital leaders, as well as the increasing need for interdepartmental collaboration to deliver solutions that again, are geared to achieving that triple aim of improving care, improving the health of populations and reducing per capita costs.

Second, we have rolled in our sister publication, Healthcare Technology Management. So much of what CMIOs, CIOs, clinical technology managers and other healthcare innovation and technology leaders do overlaps and intersects. Our perspective has broadened, reaching from the C-suite to the leaders in the IT department to the leaders in the CE department in an effort to help hospital executives provide a better understanding to their colleagues about the varied workflows and needs, with everyone working toward that triple aim. We look forward to the greater opportunity to provide readers with even more useful, informative content.

The magazine will now have a Technology Management section, and this month's issue features articles on computerized maintenance management systems, medical device integration with EMRs and using cloud technology for disaster recovery. Our technology editor, Dave Pearson, will offer his thoughts on the latest developments in this arena within each issue.

We plan to offer more stories about health IT innovations—from new products and apps to the cropping up of innovation centers, along with more insight from innovation officers—through our new Data Extracts section, as well as through longer feature stories. Clearly this is an area of rapid growth with exciting possibilities. Successful innovation and technology will require hospital departments to work together with the ultimate goal of blurring and converging their boundaries.

Thank you for joining us, as we provide the forum to share your ideas with the leadership community who is seeking to transform healthcare.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.